Login to Your Account



STAY AWAY FROM THAT ERK INHIBITOR

Modified anticoagulant gets tumor cells to commit

By Anette Breindl
Science Editor

Friday, June 20, 2014
In findings that report counterintuitive results about both the anticoagulant heparin and the receptor tyrosine kinase ERK, scientists at Duke University have shown that by treating animals with a heparin derivative, they were able to increase the differentiation of immature cells in an animal model of neuroblastoma.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription